Stay updated with breaking news from Randomized Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Scemblix® (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif®* (bosutinib) at 96...
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial
Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif* (bosutinib) at 96 weeks (37.6% vs. 15.8%), building on 24-week
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
MAU868, a first-in-class monoclonal antibody, was well tolerated in kidney transplant recipients with BK viremiaData presented as oral late breaker at...